1 / 1
Custom Deslorelin CAS 57773-65-6 – Premium GnRH Analog from China Suppliers & Factory Manufacturers, Pricelist
Product Description
Deslorelin is a synthetic gonadotropin-releasing hormone (GnRH) analog with a potency approximately 30–150 times that of natural GnRH. As a GnRH agonist, it initially and briefly stimulates the pituitary gland to release gonadotropins (the "flare-up" effect). Subsequently, through sustained agonistic action, it leads to pituitary desensitization and downregulation of GnRH receptors, thereby inhibiting the secretion of gonadotropins (LH, FSH) and ultimately suppressing the production of sex steroid hormones.
Therapeutic Areas
Veterinary application (approved)
Animal reproductive management: Widely used for reproductive suppression or estrus cycle regulation in animals such as dogs, cats, and horses, such as suppressing estrus in female dogs and controlling sexual behavior in male horses.
Treatment of animal diseases: Used to treat diseases related to sex hormones, such as prostate disease and hyperadrenocorticism in dogs.
Human medical applications (some are in the research/development stage)
Reproductive endocrine disorders: It has been studied for the treatment of hormone-dependent diseases such as precocious puberty, endometriosis, and uterine fibroids.
Prostate cancer and breast cancer: As a GnRH agonist, it can theoretically be used as adjuvant therapy for hormone-sensitive tumors, but other analogues (such as leuprorelin and goserelin) are more commonly used.
Assisted reproductive technology: Pituitary downregulation in controlled ovarian stimulation (COS) cycles has been explored, but the current mainstream clinical drugs are other GnRH analogs.
Outlook & Development
Veterinary application (approved)
Animal reproductive management: Widely used for reproductive suppression or estrus cycle regulation in animals such as dogs, cats, and horses, such as suppressing estrus in female dogs and controlling sexual behavior in male horses.
Treatment of animal diseases: Used to treat diseases related to sex hormones, such as prostate disease and hyperadrenocorticism in dogs.
Human medical applications (some are in the research/development stage)
Reproductive endocrine disorders: It has been studied for the treatment of hormone-dependent diseases such as precocious puberty, endometriosis, and uterine fibroids.
Prostate cancer and breast cancer: As a GnRH agonist, it can theoretically be used as adjuvant therapy for hormone-sensitive tumors, but other analogues (such as leuprorelin and goserelin) are more commonly used.
Assisted reproductive technology: pituitary downregulation in controlled ovarian stimulation (COS) cycles has been explored, but the current mainstream clinical drugs are other GnRH analogs.
Conclusion
Deslorelin, as a GnRH agonist, is currently primarily valued in the veterinary field, particularly as a mature tool for companion animal reproductive control. In human medicine, its development has stalled due to market competition and patent issues. Future breakthroughs may depend on novel delivery systems or targeted therapy innovations, but it is unlikely to change the existing treatment landscape in the short term.
Frequently Asked Questions (FAQ)
1. What is Deslorelin and how does it work?
Deslorelin is a synthetic gonadotropin-releasing hormone (GnRH) analog. It acts as a GnRH agonist, initially stimulating the pituitary gland to release gonadotropins, followed by desensitization and downregulation of GnRH receptors, which ultimately suppresses the production of sex steroid hormones.
2. What are the main veterinary applications of Deslorelin?
In the veterinary field, it is widely approved and used for animal reproductive management (such as suppressing estrus in female dogs and controlling sexual behavior in male horses) and for treating sex hormone-related diseases like prostate disease and hyperadrenocorticism in dogs.
3. Can Deslorelin be used in human medicine?
Yes, but mostly in the research and development stages. It has been studied for reproductive endocrine disorders (like endometriosis and uterine fibroids), hormone-sensitive tumors (prostate and breast cancer), and assisted reproductive technology, though other analogs are currently more mainstream.
4. Why is Deslorelin not the primary choice for human treatments?
Its development in human medicine has largely stalled due to intense market competition from other established GnRH analogs, such as leuprorelin and goserelin, as well as various patent-related issues.
5. Does Deslorelin cause an immediate suppression of hormones?
No, it initially causes a brief "flare-up" effect by stimulating the pituitary gland to release gonadotropins before sustained agonistic action leads to downregulation and subsequent hormone suppression.
6. What is the future outlook for Deslorelin?
While it remains a mature and valued tool in veterinary medicine, future breakthroughs in human applications may depend on the development of novel delivery systems or targeted therapy innovations. It is unlikely to significantly alter the existing treatment landscape in the short term.
